Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,170 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pediatric Tumors Clear all
Completed No phase listed Observational Accepts healthy volunteers Results available

Home Away From Home - Quality of Life Surveys

NCT02777021
View directory record Official record
Conditions
Pediatric Acute Myeloid Leukemia
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
15
States / cities
Little Rock, Arkansas • Palo Alto, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Oct 30, 2026, 6:12 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

NCT07630974
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Ifinatamab Deruxtecan
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Month to 17 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
15
States / cities
Los Angeles, California • Aurora, Colorado • St. Petersburg, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 30, 2026, 6:12 AM EDT
Recruiting Not applicable Interventional

Shareholder-driven Co-design and Piloting of Spanish Educational Videos About High Yield Pediatric Oncology Topics

NCT07288476
View directory record Official record
Conditions
Pediatric Cancer
Interventions
educational video
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 30, 2026, 6:12 AM EDT
Recruiting Phase 2 Interventional

Study of Olutasidenib and Temozolomide in HGG

NCT06161974
View directory record Official record
Conditions
High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma, WHO Grade IV Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Thalamus Tumor, Spinal Tumor, IDH1 Mutation, IDH1 R132, IDH1 R132C, IDH1 R132H, IDH1 R132S, IDH1 R132G, IDH1 R132L, Oligodendroglioma
Interventions
Olutasidenib + TMZ
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
12 Years to 39 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
11
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 30, 2026, 6:12 AM EDT
Completed Phase 2 Interventional Results available

Radioactive Iodide Therapy for Pediatric Graves' Disease

NCT01269749
View directory record Official record
Conditions
Graves' Disease
Interventions
RAI treatment, ATD Group
Radiation · Drug
Lead sponsor
University of Florida
Other
Eligibility
Up to 18 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Gainesville, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 30, 2026, 6:12 AM EDT
Recruiting No phase listed Observational

International Rare Brain Tumor Registry

NCT05697874
View directory record Official record
Conditions
Astroblastoma, BCOR ITD Sarcoma, CNS Sarcoma, Unclassified Tumor, Malignant
Interventions
Not listed
Lead sponsor
Children's National Research Institute
Other
Eligibility
Up to 45 Years
Enrollment
5,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 30, 2026, 6:12 AM EDT
Terminated Phase 1 Interventional Results available

Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors

NCT03050450
View directory record Official record
Conditions
Central Nervous System Tumors
Interventions
25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®), 50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®), 100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®), 150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®), 150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)
Drug
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
1 Year to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 30, 2026, 6:12 AM EDT
Not listed Phase 1 Interventional

Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features

NCT00314925
View directory record Official record
Conditions
Carcinoid, Neuroendocrine
Interventions
Seneca Valley Virus (biological agent)
Drug
Lead sponsor
Neotropix
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Ocoee, Florida • Indianapolis, Indiana • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2010 · Synced Oct 30, 2026, 6:12 AM EDT
Completed Phase 2 Interventional Results available

Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors

NCT00365768
View directory record Official record
Conditions
Kidney Cancer, Leukemia, Lymphoma, Neurotoxicity, Peripheral Neuropathy, Sarcoma
Interventions
Glutamine, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
5 Years to 21 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 30, 2026, 6:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Education Tools to Support Pediatric Survivor Care

NCT04257058
View directory record Official record
Conditions
Cancer, Pediatric Cancer
Interventions
Electronic educational material
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 25 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 30, 2026, 6:12 AM EDT
Recruiting Not applicable Interventional

Feasibility and Acceptability of Internet-based Parent-child Interaction Therapy (I-PCIT) in Pediatric Cancer

NCT06346782
View directory record Official record
Conditions
Pediatric Cancer, Oncology, Disruptive Behavior
Interventions
Internet-Based Parent-Child Interaction Therapy
Behavioral
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 30, 2026, 6:12 AM EDT
Completed No phase listed Observational

Sleep in Hospitalized Children at MSKCC

NCT02836041
View directory record Official record
Conditions
Pediatric Cancer Patients
Interventions
questionnaires, actigraph
Behavioral · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
0 Months to 18 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 30, 2026, 6:12 AM EDT
Not yet recruiting Phase 1 Interventional

IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)

NCT06946680
View directory record Official record
Conditions
High-grade Glioma, Diffuse Intrinsic Pontine Glioma
Interventions
Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells
Biological
Lead sponsor
University of Florida
Other
Eligibility
4 Years to 30 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2045
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 30, 2026, 6:12 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

NCT03834961
View directory record Official record
Conditions
Central Nervous System Neoplasm, Infantile Fibrosarcoma, Recurrent Acute Leukemia, Refractory Acute Leukemia, Solid Neoplasm
Interventions
Larotrectinib Sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
78
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 30, 2026, 6:12 AM EDT
Completed No phase listed Observational

Examination of Sleep and Family Functioning in Pediatric Craniopharyngioma Patients

NCT03330080
View directory record Official record
Conditions
Craniopharyngioma
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
8 Years to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 30, 2026, 6:12 AM EDT
Recruiting No phase listed Observational

Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

NCT06098430
View directory record Official record
Conditions
Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
8 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Palo Alto, California • Aurora, Colorado • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 30, 2026, 6:12 AM EDT
Terminated No phase listed Observational

Exploring The Role Of Palliative Care In Phase 1 Enrolled Pediatric Oncology Patients

NCT05412563
View directory record Official record
Conditions
Quality of Life
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
31 participants
Timeline
2022 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 30, 2026, 6:12 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

NCT04730349
View directory record Official record
Conditions
Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma, Medulloblastoma, Miscellaneous Brain Tumors, Miscellaneous Solid Tumors, Neuroblastoma, Relapsed, Refractory Malignant Neoplasms, Rhabdomyosarcoma
Interventions
Nivolumab, NKTR-214
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Up to 30 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Little Rock, Arkansas • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 30, 2026, 6:12 AM EDT
Active, not recruiting Phase 1 Interventional

CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma

NCT03684889
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
SCRI-huCAR19v1, SCRI-huCAR19v2
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 30 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
2
States / cities
Los Angeles, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 6:12 AM EDT
Completed No phase listed Observational

Interactions of Environmental and Human Microbial Communities in a Pediatric Oncology Hospital

NCT02948335
View directory record Official record
Conditions
Infection
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 30, 2026, 6:12 AM EDT
Completed No phase listed Observational

Pediatric Vaccinations

NCT04936776
View directory record Official record
Conditions
Pediatric ALL, Vaccination, Immunization
Interventions
Text messaging
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
1 Year to 2 Years
Enrollment
1,034 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 30, 2026, 6:12 AM EDT
Active, not recruiting No phase listed Observational

New Ways of Doing Magnetic Resonance Imaging in Children and Adults

NCT04643015
View directory record Official record
Conditions
Pediatric Disorder, Adult Disease
Interventions
MRI
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 30, 2026, 6:12 AM EDT
Completed Early Phase 1 Interventional

Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults

NCT03445858
View directory record Official record
Conditions
Childhood Solid Tumor, Childhood Lymphoma, Relapsed Cancer, Refractory Cancer, Adult Solid Tumor, Adult Lymphoma
Interventions
Pembrolizumab, Decitabine, Hypofractionated Index Site Radiation
Drug · Radiation
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Months to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 30, 2026, 6:12 AM EDT
Active, not recruiting Phase 1 Interventional

A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia

NCT01683279
View directory record Official record
Conditions
B Cell Leukemia
Interventions
Autologous CD19 CAR+ EGFTt + T cells
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 26 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 30, 2026, 6:12 AM EDT